Targeted Genetics news from FierceBiotech
NewsTargeted Genetics reports tgAAC94 data
Targeted Genetics is reporting results from an early-stage study of tgAAC94 for inflammatory arthritis. The drug uses a specially engineered virus to transport a gene. When working properly, the Read more...
Gene therapy trial to resume after patient's death
The gene therapy field is breathing a mighty sigh of relief after Targeted Genetics Read more...
SPOTLIGHT: Targeted Genetics hits back against trial report
Targeted Genetics went on the attack after The Washington Post raised serious criticisms of a gene therapy trial that was suspended after the death of a volunteer. But Wired also Read more...
| Press ReleasesPRESS RELEASE: Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 Targeted Genetics Announces That FDA Has Removed Hold on Phase I/II Clinical Trial of tgAAC94 for Inflammatory Arthritis Phase II Clinical Trial Protocol Design Underway SEATTLE, WA, Nov 26, Read more... |
Get more Targeted Genetics coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets